Tasa de interrupción de la terapia antirretroviral dual con dolutegravir más lamivudina en personas que viven con el VIH: una revisión sistemática

Autor: Silveira, Marina Rezende da, Souza-Silva, Gabriel de, Mendes, Jullye Campos, Santos, Simone Furtado dos, Souza, Clessius Ribeiro Ribeiro de, Silveira, Micheline Rosa

Publikováno v: Research, Society and Development; Vol. 11 No. 12; e430111234758
Research, Society and Development; Vol. 11 Núm. 12; e430111234758
Research, Society and Development; v. 11 n. 12; e430111234758
Research, Society and Development
Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI

Antiretroviral therapies are used as a way to improve the life expectancy of people living with HIV. With the reduction of adverse effects, dual therapy with dolutegravir (DTG) plus lamivudine (3TC) has proved to be a viable option. However, even wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::80aec65884c395c30d929f479a6b5576
https://rsdjournal.org/index.php/rsd/article/view/34758